Aptose Biosciences Inc. (APTO) CFO Acquires $26,250.00 in Stock

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CFO Gregory K. Chow bought 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was acquired at an average cost of $1.75 per share, with a total value of $26,250.00. Following the completion of the acquisition, the chief financial officer now owns 122,014 shares of the company’s stock, valued at approximately $213,524.50. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of APTO stock traded up $0.09 on Thursday, reaching $1.90. The company’s stock had a trading volume of 272,499 shares, compared to its average volume of 272,055. Aptose Biosciences Inc. has a 1 year low of $1.57 and a 1 year high of $4.55. The firm has a market cap of $70.99 million, a PE ratio of -2.21 and a beta of 1.59.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). As a group, research analysts anticipate that Aptose Biosciences Inc. will post -0.68 EPS for the current fiscal year.

A number of research firms recently weighed in on APTO. Zacks Investment Research lowered shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 8th. Roth Capital reissued a “buy” rating on shares of Aptose Biosciences in a report on Wednesday, December 12th. Citigroup began coverage on shares of Aptose Biosciences in a report on Friday, January 25th. They issued an “outperform” rating and a $6.00 target price for the company. HC Wainwright set a $9.00 target price on shares of Aptose Biosciences and gave the company a “buy” rating in a report on Thursday, December 13th. Finally, Royal Bank of Canada began coverage on shares of Aptose Biosciences in a report on Friday, March 1st. They issued an “outperform” rating and a $6.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $5.79.

A number of hedge funds and other institutional investors have recently bought and sold shares of APTO. Citadel Advisors LLC purchased a new position in Aptose Biosciences during the third quarter worth $125,000. Renaissance Technologies LLC boosted its stake in Aptose Biosciences by 1,130.9% during the third quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock worth $477,000 after buying an additional 168,501 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its stake in Aptose Biosciences by 11.4% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock worth $110,000 after buying an additional 5,890 shares during the period. Noven Financial Group Inc. purchased a new position in Aptose Biosciences during the fourth quarter worth $27,000. Finally, Geode Capital Management LLC purchased a new position in Aptose Biosciences during the fourth quarter worth $33,000. 8.19% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2019/03/14/aptose-biosciences-inc-apto-cfo-acquires-26250-00-in-stock.html.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

See Also: Insider Trading

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.